Literature DB >> 8172435

Risk factors for intracranial hemorrhage in outpatients taking warfarin.

E M Hylek1, D E Singer.   

Abstract

OBJECTIVE: To explore the rational use of anticoagulants, especially among the elderly, balancing antithrombotic efficacy and risk for hemorrhage. Previous prospective studies have not provided powerful assessments of risk factors for intracranial hemorrhage, the dominant complication in reversing the anticoagulant decision.
DESIGN: Case-control analysis.
SETTING: A large general hospital and its anticoagulant therapy unit. PATIENTS: 121 consecutive adult patients taking warfarin who were hospitalized with intracranial hemorrhage were each matched to three contemporaneous controls randomly selected from among outpatients managed by our hospital anticoagulant therapy unit.
RESULTS: 77 patients had intracerebral hemorrhage (46% fatal) and 44 had subdural hemorrhage (20% fatal). The prothrombin time ratio (PTR) was the dominant risk factor for intracranial hemorrhage. For each 0.5 increase in PTR over the entire range, the risk for intracerebral hemorrhage doubled (odds ratio, 2.1; 95% CI, 1.4 to 2.9). For subdural hemorrhage, the risk was unchanged over the PTR range from 1.0 to 2.0 but rose dramatically above a PTR of 2.0 (approximate international normalized ratio, 4.0). Age was the only other significant independent risk factor for subdural hemorrhage (odds ratio, 2.0 per decade; CI, 1.3 to 3.1). For intracerebral hemorrhage, age was of borderline significance (odds ratio, 1.3 per decade; CI, 1.0 to 1.6) after controlling for PTR and the two other independent risk factors: history of cerebrovascular disease (odds ratio, 3.1; CI, 1.7 to 5.6) and presence of a prosthetic heart valve (odds ratio, 2.8; CI, 1.3 to 5.8).
CONCLUSIONS: The results emphasize the importance of maintaining the prothrombin time ratios under 2.0 and the need for especially careful use of warfarin in the elderly.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8172435     DOI: 10.7326/0003-4819-120-11-199406010-00001

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  160 in total

Review 1.  Out-of-hospital coagulation monitoring and management.

Authors:  J E Ansell
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use.

Authors:  D McCormick; J H Gurwitz; R J Goldberg; J Ansell
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

3.  Anticoagulation Management as a Risk Factor for Adverse Events: Grounds for Improvement.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-01       Impact factor: 2.300

Review 4.  Use of oral anticoagulants in older patients.

Authors:  J L Sebastian; D D Tresch
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

5.  High-risk antimicrobial prescriptions among ambulatory patients on warfarin.

Authors:  M A Lane; S T Devine; J R McDonald
Journal:  J Clin Pharm Ther       Date:  2011-04-24       Impact factor: 2.512

Review 6.  Guidelines for stroke prevention in patients with atrial fibrillation.

Authors:  P A Howard
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

7.  Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy.

Authors:  Andrea Rubboli; Cecilia Becattini; Freek Wa Verheugt
Journal:  World J Cardiol       Date:  2011-11-26

8.  The role of delayed head CT in evaluation of elderly blunt head trauma victims taking antithrombotic therapy.

Authors:  D Scantling; C Fischer; R Gruner; A Teichman; B McCracken; J Eakins
Journal:  Eur J Trauma Emerg Surg       Date:  2017-04-24       Impact factor: 3.693

9.  A new regimen for starting warfarin therapy in out-patients.

Authors:  A Oates; P R Jackson; C A Austin; K S Channer
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

10.  Paracetamol: a haemorrhagic risk factor in patients on warfarin.

Authors:  I Mahé; N Bertrand; L Drouet; G Simoneau; E Mazoyer; C Bal dit Sollier; C Caulin; J F Bergmann
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.